Nivolumab Immune-Mediated Pneumonitis

Am J Ther. 2020 Nov/Dec;27(6):e617-e618. doi: 10.1097/MJT.0000000000000945.
No abstract available

MeSH terms

  • Carcinoma, Non-Small-Cell Lung*
  • Humans
  • Lung Neoplasms* / drug therapy
  • Nivolumab / adverse effects
  • Pneumonia* / chemically induced
  • Pneumonia* / drug therapy

Substances

  • Nivolumab